Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Staladex 11.25mg Implant

Active Ingredient:
leuprorelin acetate
Aspire Pharma Ltd See contact details
ATC code: 
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 13 Mar 2024
1. Name of the medicinal product

Staladex 11.25 mg Implant

2. Qualitative and quantitative composition

Each implant contains 11.25 mg leuprorelin acetate (equivalent as 10.72 mg leuprorelin). For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Implant in a pre-filled syringe

White to off-white cylindrical rod (approximate dimensions: length 17.8 mm, diameter 1.5 mm)

4. Clinical particulars
4.1 Therapeutic indications

(i) Metastatic prostate cancer.

(ii) Locally advanced prostate cancer, as an alternative to surgical castration.

(iii) As an adjuvant treatment to radiotherapy in patients with high-risk localized or locally advanced prostate cancer.

(iv) As an adjuvant to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression.

(v) As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.

4.2 Posology and method of administration


Administer one implant once every three months.

Method of administration

Staladex should be administered only by healthcare professionals.

Staladex is injected subcutaneously under the abdominal skin.

Animal study findings (thrombosis of small vessels distal to the administration site) indicate that accidental intra-arterial injection must be avoided.

Response to Leuprorelin therapy should be monitored by clinical parameters and by measuring prostate-specific antigen (PSA) serum levels. Clinical studies with leuprorelin acetate have shown that testosterone levels increased during the first 4 days of treatment in the majority of non-orchidectomised patients. They then decreased and reached castrate levels by 2-4 weeks. Once attained, castrate levels were maintained as long as drug therapy continued. If a patient's response appears to be sub-optimal, then it would be advisable to confirm that serum testosterone levels have reached or are remaining at castrate levels.

In patients treated with GnRH analogues for prostate cancer, treatment is usually continued upon development of castrate-resistant prostate cancer. Reference should be made to relevant guidelines.

Treatment of advanced, hormone-dependent prostate cancer with Leuprorelin is usually a long-term treatment.

Clinical data have shown that 3 years of androgen deprivation therapy used concomitantly with and after radiotherapy is preferable to a 6-month course of androgen deprivation therapy in locally advanced, hormone-dependent prostate cancer (see also section 5.1). Medical guidelines recommend a 2- to 3-year course of androgen deprivation therapy for patients (T3 - T4) receiving radiotherapy.

4.3 Contraindications

• Hypersensitivity to leuprorelin or other GnRH analogues, or to any of the implant excipients listed in section 6.1.

• Patients who previously underwent orchiectomy.

• As the sole treatment in prostate cancer patients with spinal cord compression or evidence of spinal metastases.

• In women or paediatric patients.

4.4 Special warnings and precautions for use

Transient testosterone flare:

In the initial stages of therapy, a transient rise in levels of testosterone, dihydrotestosterone and acid phosphatase may occur. In some cases, this may be associated with a "flare" or exacerbation of the tumour growth resulting in temporary deterioration of the patient's condition. These symptoms usually subside on continuation of therapy. "Flare" may manifest itself as systemic or neurological symptoms in some cases.

In order to reduce the risk of “ flare” , an anti-androgen may be administered beginning 3 days prior to leuprorelin therapy and continuing for the first two to three weeks of treatment. This has been reported to prevent the sequelae of an initial rise in serum testosterone.

Following surgical castration, Leuprorelin does not lead to a further decrease in serum testosterone levels in male patients.

Therapeutic success should be monitored regularly (but particularly if there is evidence of progression despite appropriate treatment) by means of clinical examinations (digital rectal examination of the prostate, ultrasound, skeletal scintigraphy, computed tomography) and by checking phosphatases and/or PSA and serum testosterone.

Cases of ureteral obstruction and spinal cord compression, which may contribute to paralysis with or without fatal complications, have been reported with GnRH agonists. If spinal cord compression or renal impairment develops, standard treatment of these complications should be instituted.

Patients with vertebral and/or brain metastases as well as patients with urinary tract obstruction should be closely monitored during the first few weeks of therapy.

Patients with hypertension should be carefully monitored.

Bone density:

Long-term androgen deprivation either by bilateral orchiectomy or administration of GnRH analogues is associated with increased risk of bone loss which, in patients with additional risk factors, may lead to osteoporosis and increased risk of bone fracture..

Apart from long lasting testosterone deficiency, increased age, smoking and consumption of alcoholic beverages, obesity and insufficient exercise may have an influence on the development of osteoporosis.

Pituitary apoplexy:

During post-marketing surveillance, rare cases of pituitary apoplexy (a clinical syndrome secondary to infarction of the pituitary gland) have been reported after the administration of GnRH-agonists, with a majority occurring within 2 weeks of the first dose, and some within the first hour. In these cases, pituitary apoplexy was presented as sudden headache, vomiting, visual changes, ophthalmoplegia, altered mental status, and sometimes cardiovascular collapse. Immediate medical attention is required.


There is an increased risk of incident depression (which may be serious) in patients undergoing treatment with GnRH agonists, such as leuprorelin. Patients should be informed of this risk and treated as appropriate if symptoms occur.


There have been post-marketing reports of convulsions observed in patients treated with leuprorelin acetate and these events have been reported in both children and adults with or without a history of epilepsy, seizure disorders or risk factors for seizures.

The use of Leuprorelin can produce positive results in doping tests.

Metabolic changes and cardiovascular risk:

Epidemiological data have shown that during androgen-deprivation therapy, changes in metabolism (e.g. reduction in glucose tolerance or aggravation of pre- existing diabetes mellitus) as well as an increased risk for cardiovascular diseases may occur. However, prospective data did not confirm the link between treatment with GnRH analogues and an increase in cardiovascular mortality. Patients with diabetes and those at increased risk of metabolic or cardiovascular diseases should be appropriately monitored.

As would be expected with this class of drug, development or aggravation of diabetes may occur, therefore diabetic patients may require more frequent monitoring of blood glucose during treatment with Staladex.

Androgen deprivation therapy may prolong the QT interval.

In patients with a history of or risk factors for QT interval prolongation and in patients receiving concomitant medicinal products known to prolong the QT interval (see section 4.5) physicians should carefully assess the benefit/risk ratio including the potential for developing torsade de pointes prior to initiating therapy with Staladex.

Hepatic dysfunction:

Hepatic dysfunction and jaundice with elevated liver enzyme levels have been reported with the use of leuprorelin acetate. Therefore, close observation should be made and appropriate measures taken if necessary.

Injection site abscesses

Abscesses at the injection site occur rarely. In one report of an abscess at the injection site, the absorption of leuprorelin from the depot appeared to be decreased. It is therefore advised to determine testosterone levels in such cases.

Idiopathic intracranial hypertension

Idiopathic intracranial hypertension (pseudotumor cerebri) has been reported in patients receiving leuprorelin. Patients should be warned for signs and symptoms of idiopathic intracranial hypertension, including severe or recurrent headache, vision disturbances and tinnitus. If idiopathic intracranial hypertension occurs, discontinuation of leuprorelin should be considered.

4.5 Interaction with other medicinal products and other forms of interaction

No pharmacokinetic drug-drug interaction studies have been performed with Staladex. There have been no reports of any interactions of leuprorelin acetate with other medicinal products

Since androgen deprivation therapy may prolong the QT interval, the concomitant use of Staladex with other medicinal products known to prolong the QT interval or medicinal products able to induce torsade de pointes, such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics etc, should be carefully evaluated (see section 4.4).

4.6 Fertility, pregnancy and lactation

Staladex is not indicated for use in women and is generally contraindicated during pregnancy and lactation.

4.7 Effects on ability to drive and use machines

No studies on the effects of Leuprorelin on the ability to drive and use machines have been performed. However, the ability to drive and use machines may be impaired due to visual disturbances and dizziness.

Fatigue is common, particularly during initiation of therapy, and may also be due to the underlying malignancy.

4.8 Undesirable effects

Adverse reactions seen with Staladex are due mainly to the specific pharmacological action, namely increases and decreases in certain hormone levels.

In cases where a "tumour flare" occurs after therapy, an exacerbation may occur in any symptoms or signs due to disease, for example bone pain, urinary obstruction, weakness of the lower extremities and paraesthesia). These symptoms usually subside on continuation of therapy.

The following tables list adverse reactions with leuprorelin based on experience from clinical trials as well as from post-marketing experience. Adverse reactions are grouped by MedDRA System Organ Classes and frequency classification.

Frequencies are defined as:

very common (≥ 1/10),

common (≥ 1/100 to <1/10),

uncommon (≥ 1/1,000 to <1/100),

rare (≥ 1/10,000 to <1/1,000),

very rare (<1/10,000),

not known (cannot be estimated from the available data).

Table 1. Undesirable effects

Blood and lymphatic system disorders

Not known

Anaemia (reported in medicinal products of this class), thrombocytopaenia, leucopenia

Immune system disorders

Not known

Hypersensitivity reactions (including rash. pruritus, urticaria and rarely, wheezing and interstitial pneumonitis, anaphylactic reactions)

Metabolism and nutrition disorders

Very common

Weight fluctuation


Decreased appetite, l

Not known

Lipids abnormal, glucose tolerance abnormal

Psychiatric disorders


Insomnia, depression (see section 4.4), mood changes (long-term use)**

Nervous system disorders


Headache (occasionally severe)


Dizziness, paraesthesia

Very rare

Pituitary apoplexy has been reported following initial administration in patients with pituitary adenoma.

Not known

Paralysis (see section 4.4), seizure, idiopathic intracranial hypertension (pseudotumor cerebri) (see section 4.4)

Eye disorders

Not known

Visual impairment

Cardiac disorders

Not known

QT interval prolonged (see sections 4.4 and 4.5), palpitations

Vascular disorders

Very common

Hot flushes

Not known

Pulmonary embolism, hypertension, hypotension (see section 4.4)

Gastrointestinal disorders




Diarrhoea, vomiting

Hepatobiliary disorders


Hepatic function abnormal, liver function test abnormal (usually transient)

Not known


Skin and subcutaneous tissue disorders

Very common


Musculoskeletal and connective tissue disorders

Very common

Muscle weakness, bone pain




Myalgia, weakness of lower extremities

Not known

Spinal fracture (see section 4.4), reduction in bone mass which may occur with the use of GnRH agonists

Renal and urinary disorders

Not known

Urinary tract obstruction

Reproductive system and breast disorders

Very common

Libido decreased, erectile dysfunction, testiculars atrophy



Respiratory, thoracic and mediastinal disorders

Not known

Interstitial lung disease

General disorders and administration site conditions

Very common

Fatigue, injection site reactions e.g. induration, erythema, pain, abscesses, swelling, nodules, ulcers and necrosis.


Peripheral oedema

Not known


** mood changes (long term use: frequency of 'common' and short term use: frequency of 'uncommon'

Special notes:

It is advisable the response to Leuprorelin therapy is monitored by measuring serum concentrations of testosterone 28 days after each injection carried out and before each re-administration of Staladex and additionally on the basis of other laboratory tests like acid phosphatase and PSA. For example, testosterone levels show an initial surge upon initiation of therapy, only to decrease thereafter over a period of two weeks.

After two to four weeks, testosterone concentrations reach levels similar to those observed following bilateral orchiectomy and remain at that level throughout the treatment period.

An increase in acid phosphatase levels may be seen in the initial phase of treatment and is transient in nature. Acid phosphatase usually returns to normal levels or near- normal levels after a few weeks.

Abscesses at the injection site occur rarely. In one report of an abscess at the injection site, the absorption of leuprorelin from the depot appeared to be decreased. It is therefore advised to determine testosterone levels in such cases.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

No case of overdose has been reported.

Even when administering doses of up to 20 mg leuprorelin acetate per day for two years ( the dose levels used in early clinical studies), no other or new adverse reactions differing from those seen after daily administration of 1 mg or three- monthly administration of 11.25 mg were observed.

In cases of overdose, the patients should be monitored closely and management should be symptomatic and supportive

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: GnRH analogues, ATC code: L02AE02

Leuprorelin acetate, the active substance of Staladex, is a synthetic analogue of the naturally occurring hypothalamic releasing factor GnRH, which controls the release of the gonadotropic hormones LH (luteinising hormone) and FSH (follicle- stimulating hormone) from the anterior lobe of the pituitary gland. These hormones in turn stimulate gonadal steroid synthesis.

Unlike physiological GnRH, which is released in a pulsatile manner from the hypothalamus, leuprorelin acetate – also known as GnRH agonist – blocks pituitary GnRH receptors continuously during long-term therapeutic use and, after initial short- term stimulation, causes their desensitisation (down regulation).


As a result, there is reversible pituitary suppression of gonadotropin release with a subsequent drop in testosterone concentrations in men, which in turn influences the growth of carcinomatous prostate tissue which is normally stimulated by dihydrotestosterone, formed by the reduction of testosterone in prostate cells.

Continuous administration of leuprorelin acetate leads to a decrease in the number and/or sensitivity (down regulation) of pituitary receptors and consequently to a decrease in LH, FSH and DHT levels. This causes testosterone concentrations to be reduced to castration levels.

An anti-androgenic effect and growth inhibition of prostatic carcinomas have also been demonstrated in animal studies.

Experimental and clinical studies have shown that three-monthly treatment with leuprorelin acetate inhibits the release of gonadotropin after initial stimulation.

In men, subcutaneous administration of leuprorelin acetate causes an initial increase in LH and FSH, characterised by a transient increase in testosterone and dihydrotestosterone levels.

In isolated cases, an associated short-term symptomatic aggravation of the disease has been observed in the first three weeks; consideration should therefore be given to adjuvant anti-androgen therapy in men with prostate cancer.

In contrast, long-term treatment with leuprorelin acetate causes a decrease in LH and FSH concentrations in all patients; in men, androgen concentrations similar to those seen following bilateral orchiectomy are reached. These changes usually appear two to three weeks after the start of therapy and are maintained throughout the treatment period. This is also the reason why leuprorelin acetate can be used to test the hormone sensitivity of prostate cancer and the potential therapeutic value of orchiectomy.

Orchiectomy may be replaced with three-monthly administration of leuprorelin acetate in selected cases. So far, it has been possible to maintain castrate testosterone levels following continuous administration of leuprorelin acetate for five years.

Clinical efficacy

A phase 3 multicentre, randomised study of leuprorelin acetate evaluated 263 patients with stage T3 - T4 or pT3, N0, M0 locally advanced prostate cancer. 133 patients received a combination of radiotherapy plus long-term androgen deprivation therapy for 3 years, and 130 patients received 3 years' of androgen deprivation therapy with leuprorelin acetate alone.

Based on ASTRO (Phoenix) criteria, the 5-year progression-free survival was 60.9% (64.7%) in the combination therapy group compared to 8.5% (15.4%) in the group receiving hormone therapy alone [p=0.0001; (p=0.0005)]. Based on ASTRO criteria, the progression risk was 3.8-fold greater in the group receiving hormone therapy alone (95% CI [2.17; 6.49]).

The median clinical or biochemical progression-free survival, as defined by ASTRO, was 641 days (95% CI [626; 812]) in the group receiving ADT alone versus 2,804 days (95% CI [2,090; -]; p<0.0001) in the combination therapy group. There were additional statistically significant differences in locoregional progression [HR 3.6 (95% CI [1..9; 6.8]; p<0.0001)], metastatic progression (p<0.018) and metastasis- free survival (p=0.018) for the combination therapy group versus the group receiving androgen deprivation therapy alone.

The results of this study showed that 3 years of androgen deprivation therapy with leuprorelin acetate in combination with radiotherapy was superior to 3 years of androgen deprivation therapy with leuprorelin acetate alone.

Evidence for the indication of high-risk localized prostate cancer is based on published studies of radiotherapy combined with GnRH analogues, including leuprorelin acetate. Clinical data from five published studies were analyzed (EORTC 22863, RTOG 85-31, RTOG 92-02, RTOG 8610, and D'Amico et al., JAMA, 2004), which all demonstrate a benefit for the combination of GnRH analogue with radiotherapy. Clear differentiation of the respective study populations for the indications locally advanced prostate cancer and high-risk localized prostate cancer was not possible in the published studies.

Clinical data have shown that radiotherapy followed by 3 years of androgen deprivation therapy is preferable to radiotherapy followed by 6 months of androgen deprivation therapy.

The recommended duration of androgen deprivation therapy in medical guidelines for T3-T4 patients receiving radiotherapy is 2-3 years.

Clinical studies in patients with metastatic, castration-resistant prostate cancer have shown a benefit from additional dosing with drugs such as androgen synthesis inhibitors (e.g. abiraterone acetate), anti-androgens (e..g. enzalutamide), taxanes (e.g. docetaxel or cabazitaxel) or radiotherapeutics (e.g. radium-223) in addition to GnRH agonists such as leuprorelin acetate.

5.2 Pharmacokinetic properties


Following injection of the implant, the active substance, leuprorelin acetate, is released continuously over a period of 3 months. The polymers are absorbed like surgical suture material.


Figure 1 presents the leuprorelin plasma levels in male patients after s.c. injection of Staladex (single application). After 3 days plasma levels of 2.39 ± 1.15 ng/mL are measured. Measurable leuprorelin plasma levels are available over the whole application period.


Figure 1: Leuprorelin plasma levels [ng/mL] after s.c. application of Staladex in male patients

Distribution and elimination

The volume of distribution of leuprorelin in men is 36 l, and total clearance is 139.6 ml/min (determined when using leuprorelin acetate as a depot formulation).

Repeated dosing produces a sustained reduction in the testosterone concentration to castration levels, without the testosterone concentration showing the transient rise seen after the first injection.

Patients with renal/hepatic impairment

Leuprorelin levels in patients with renal and/or hepatic impairment were similar to those measured in patients with normal kidney and/or liver function. Some patients with chronic kidney disease showed higher leuprorelin serum levels. However, this observation appears to have no clinical significance.


The relative bioavailability after 84 days for Staladex is 84.6 %, calculated based on comparison with the AUC of an intravenous injection of 1 mg leuprorelin acetate.

5.3 Preclinical safety data

Acute toxicity (LD50)

The acute toxicity of the depot formulation was studied in male and female mice and rats by four routes (IP, IM, SC, PO). No deaths were observed up to doses of 2,000 or 5,000 mg leuprorelin acetate.

Repeated dose toxicity

Chronic toxicity studies were carried out in rats and dogs for 13 weeks (subcutaneous or intramuscular injection of up to 8 mg leuprorelin acetate/kg body weight per week) and for 12 months (subcutaneous administration of up to 32 mg leuprorelin acetate/kg body weight per month).

All dose levels (the lowest dose tested was 0.8 mg leuprorelin acetate/kg body weight per month) were associated with local skin lesions at the injection site and atrophic changes in the reproductive organs. Rats showed vacuoles in liver cells and in renal tubular epithelial cells at all dose levels. The observed reproductive organ changes are explained by the endocrinological effect of the substance.

Carcinogenicity, mutagenicity, effect on fertility


Two-year carcinogenicity studies were carried out in rats and mice. Rats showed a dose-related increase in pituitary adenomas. These findings were seen in rats after daily subcutaneous dosing with doses ranging from 0.6 to 4 mg for 24 months. Mice developed no pituitary adenomas at a dose of 60 mg/kg/day for two years.


In vitro and in vivo assays of leuprorelin acetate performed to detect gene and chromosomal mutations produced no evidence of a mutagenic potential.


Studies in sexually mature female rats dosed twice daily with leuprorelin acetate 10 μ g SC for 14 days or 40 μ g SC for 13 days showed increased organ weights of the uterus and ovaries, increased hormone levels and the appearance of fresh corpora lutea following discontinuation of the substance.

Three-month studies in immature female and male rats with continuous (200 μ g/kg body weight/day) or intermittent (0.8 or 2.4 mg/kg body weight/month) administration showed normal reproductive behaviour in the post-treatment recovery period. The F1 generation showed no abnormalities. The reproductive behaviour of the F1 generation was not studied.

Clinical and pharmacological studies in men have shown that suppression of fertility was fully reversible within not more than 24 weeks after discontinuation of continuous dosing with leuprorelin acetate.

Reproductive toxicity

Studies in rats and rabbits have produced no evidence of teratogenic potential. Embryotoxic/embryolethal effects were observed in rabbits at doses greater than 0.24 μ g/kg.

6. Pharmaceutical particulars
6.1 List of excipients

Polylactic acid

Poly(D,L-lactide-co-glycolide) (1:1)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

4 years.

The pre-filled syringe must be used immediately after opening the sterile pouch.

6.4 Special precautions for storage

Do not store above 30° C. Store the pre-filled syringe in the unopened original package.

6.5 Nature and contents of container

Plastic pre-filled syringe (with depot chamber) with stainless steel plunger and needle. The pre-filled syringe is packaged together with a desiccant in a sealed sterile plastic/aluminium foil laminate pouch.

Pack sizes (each also as hospital pack):

1 pre-filled syringe containing 1 implant

2 pre-filled syringes each containing 1 implant

4 pre-filled syringes each containing 1 implant

Bundle packs (each also as hospital pack):

2 (2x1) pre-filled syringes each containing 1 implant

4 (2x2) pre-filled syringes each containing 1 implant

4 (4x1) pre-filled syringes each containing 1 implant

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements.

7. Marketing authorisation holder

Amdeepcha Limited,

85 Yarmouth Road



United Kingdom

8. Marketing authorisation number(s)

PLGB 19255/0023

9. Date of first authorisation/renewal of the authorisation


10. Date of revision of the text


Aspire Pharma Ltd
Company image
4 Rotherbrook Court, Bedford Road, Petersfield, Hampshire, GU32 3QG, UK
+44 (0)1730 231148
Medical Information Direct Line
+44 (0)1730 231148
Customer Care direct line
+44 (0)1730 231148